Nephro-Urology Monthly

Published by: Kowsar

Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan

Atieh Makhlough 1 , 2 , Zahra Kashi 1 , * , Ozra Akha 1 , Ehsan Zaboli 3 and Jamshid Yazdanicharati 4
Authors Information
1 Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran
2 Molecular and Cellular Biology Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran
3 Mazandaran University of Medical Sciences, Sari, IR Iran
4 Department of Biostatistics and Epidemiology, Mazandaran University of Medical Sciences, Sari, IR Iran
Article information
  • Nephro-Urology Monthly: January 01, 2014, 6 (1); e12148
  • Published Online: January 14, 2014
  • Article Type: Research Article
  • Received: May 12, 2013
  • Revised: May 31, 2013
  • Accepted: June 9, 2013
  • DOI: 10.5812/numonthly.12148

To Cite: Makhlough A, Kashi Z, Akha O, Zaboli E, Yazdanicharati J. Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan, Nephro-Urol Mon. 2014 ; 6(1):e12148. doi: 10.5812/numonthly.12148.

Abstract
Copyright © 2014, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006; 1(2): 256-62[DOI][PubMed]
  • 2. Parving HH. Diabetic nephropathy: prevention and treatment. Kidney Int. 2001; 60(5): 2041-55[DOI][PubMed]
  • 3. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002; 346(15): 1145-51[DOI][PubMed]
  • 4. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2003; 26-6[PubMed]
  • 5. Bhaskar L, Mahin S, Ginila R, Soundararajan P. Role of the ACE ID and PPARG P12A Polymorphisms in Genetic Susceptibility of Diabetic Nephropathy in a South Indian Population. Nephro Urol Mon. 2013; 5(3): 813-7
  • 6. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol. 2003; 14(12): 3217-32[PubMed]
  • 7. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997; 349(9069): 1857-63[PubMed]
  • 8. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329(20): 1456-62[DOI][PubMed]
  • 9. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12): 851-60[DOI][PubMed]
  • 10. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996; 334(15): 939-45[DOI][PubMed]
  • 11. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003; 361(9352): 117-24[DOI][PubMed]
  • 12. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003; 41(1): 64-8[PubMed]
  • 13. Morishita Y, Kusano E. Direct Renin Inhibitor: Aliskiren in Chronic Kidney Disease. Nephro Urol Mon. 2011; 5(1): 668-672
  • 14. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004; 47(11): 1936-9[DOI][PubMed]
  • 15. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996; 98(4): 1063-8[DOI][PubMed]
  • 16. Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int. 1992; 41(2): 326-33[PubMed]
  • 17. Hostetter TH, Rosenberg ME, Ibrahim HN, Juknevicius I. Aldosterone in progressive renal disease. Semin Nephrol. 2001; 21(6): 573-9[PubMed]
  • 18. Otani H, Otsuka F, Inagaki K, Takeda M, Miyoshi T, Suzuki J, et al. Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation. Am J Physiol Renal Physiol. 2007; 292(5)-25[DOI][PubMed]
  • 19. Qu Y, Du E, Zhang Y, Li S, Han R, Qiu M. Changes in the Expression of Bone Morphogenetic Protein 7 and Tamm– Horsfall Protein in the Early Stages of Diabetic Nephropathy. Nephro Urol Mon. 2011; 4(2): 466-9
  • 20. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001; 345(12): 925-6[DOI][PubMed]
  • 21. Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med. 2004; 21(5): 471-5[DOI][PubMed]
  • 22. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005; 28(9): 2106-12[PubMed]
  • 23. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis. 2005; 46(1): 45-51[PubMed]
  • 24. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Cabrini G, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol. 2001; 37(7): 1808-12[PubMed]
  • 25. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345(12): 861-9[DOI][PubMed]
  • 26. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348(14): 1309-21[DOI][PubMed]
  • 27. Davidson MB, Wong A, Hamrahian AH, Stevens M, Siraj ES. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. Endocr Pract. 2008; 14(8): 985-92[PubMed]
  • 28. Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F, et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol. 2003; 14(9): 2255-63[PubMed]
  • 29. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT, Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998; 31(1 Pt 2): 451-8[PubMed]
  • 30. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care. 2002; 25(1): 95-100[PubMed]
  • 31. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int. 2004; 66(4): 1493-502[DOI][PubMed]
  • 32. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996; 78(8): 902-7[PubMed]
  • 33. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia. 1994; 37(5): 511-6[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments